Is there a role for biomarkers in thoracic aortic aneurysm disease?
Is there a role for biomarkers in thoracic aortic aneurysm disease?
复制标题
DOI：
10.1007/s11748-017-0855-0
复制
发表时间：
2019-01-01
影响因子：
1.2
通讯作者：
Bashir, Mohamad
中科院分区：
文献类型：
--
作者：
Balmforth, Damian;Harky, Amer;Bashir, Mohamad
胸主动脉瘤（TAA）是西方国家死亡率和发病率的主要原因。TAA的自然病史是无痛的，患者通常无症状，直到发生灾难性事件，如破裂或剥离。因此，早期诊断是至关重要的，目前正在寻找一种生物标志物，可以足够准确地指示TAA的存在，作为一种筛查工具。迄今为止，还没有这样的标志物被开发用于诊断非家族性或散发性TAA。然而，我们对家族性和散发性TAA发病机制的了解有所增加，这为诊断性生物标志物提供了潜在的候选物。许多标记物/途径在TAA的主动脉组织中具有不同的活性水平或表达。然而，应优先考虑在血浆中显示不同水平的标记物，因为血液检查是大规模筛查TAA的最简单途径。本综述旨在评估已经用于诊断TAA的临床试验的有效性，探索新的生物标志物，并确定未来感兴趣的关键领域。
Thoracic aortic aneurysm (TAA) represents a major cause of mortality and morbidity in Western countries. The natural history of TAA is indolent, with patients usually being asymptomatic until a catastrophic event such as rupture or dissection ensues. As such, early diagnosis is crucial and the search is ongoing for a biomarker that can indicate the presence of TAA with sufficient accuracy to act as a screening tool. To date, no such marker has been developed for the diagnosis of non-familial or sporadic' TAA. However, our increased understanding of the pathogenesis of both familial and sporadic TAA has suggested potential candidates for diagnostic biomarkers. Many markers/pathways have been shown to have differential activity levels or expression in the aortic tissue of TAA. However, priority is given to markers that have shown differential levels in blood plasma, as blood tests represent the easiest route for mass screening for TAA. This review aims to evaluate the efficacy of clinical tests already in use in diagnosing TAA, explore novel proposed biomarkers and identify key areas of future interest.